Founded company centered on applying computational approaches to the discovery of small molecule drugs from nature. Built Sirenas from an idea to an award-winning organization of >20 employees recognized by organizations including The Bill and Melinda Gates Foundation, The Smithsonian, XConomy and San Diego Magazine. Leader for immunology, oncology and infectious disease discovery teams. Accountable for core strategy and deliverables for preclinical programs including cGAS antagonist, RIG-I agonist, T cell activation, antibody drug conjugates, malaria and HIV via internal and external collaboration efforts. Sourced, negotiated to close, and oversaw alliances including Bristol-Myers Squibb, Calibr at Scripps Research, The Bill and Melinda Gates Foundation and undisclosed industry and academic partnerships.

Medical Science lead for Herceptin® gastric cancer launch, responsible for developing the US Medical Affairs strategy and tactics across Medical Affairs functions. Coordinated GI oncology MSL efforts for Avastin®, Herceptin®, Xeloda® and Tarceva®.

Marketing: Developed, managed and launched Herceptin® promotional initiatives to field sales team. Sales: Successfully launched Herceptin® label extension in HER2+ breast cancer in central Texas territory. Awarded Sales Excellence (Top 15% of sales force) in 2009.

Lead clinical operations role on a 70 patient Phase I/II proof of concept trial for an aPTHrP antibody in the treatment of bone lesions in metastatic breast cancer.

Lead clinical operations role in Expanded Access study of Bexxar® in Non Hodgkin's Lymphoma, producing safety data on 200 patients in support of filing and BLA approval.